Human evidence record · Thymalin
Peptides of pineal gland and thymus prolong human life
The report describes lower morbidity and mortality in peptide-treated groups.
Quick read
Human evidence record
What this study tells us
This is human clinical evidence. Its strength depends on the study design, sample size, comparator, population, duration and the outcome that was actually measured.
Who was studied?
Older adults
How many?
n=266
What happened?
The report describes lower morbidity and mortality in peptide-treated groups.
What stops us overclaiming?
Older regional evidence, incomplete methods in accessible abstract, unusually large claimed effects and limited independent replication; low certainty.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
The report describes lower morbidity and mortality in peptide-treated groups.
Study details
Study designLong-term regional clinical report; randomization/blinding not clear from accessible abstract
PopulationOlder adults
Sample size266
RouteRegimen not fully verifiable from abstract
Regimen / exposureThymalin and/or Epithalamin courses during early years of follow-up
Duration6–8 years follow-up
ComparatorControl group
Primary endpoint / questionMorbidity and mortality in older adults
Safety resultModern adverse-event ascertainment is not clearly described in the abstract.
Key limitationsOlder regional evidence, incomplete methods in accessible abstract, unusually large claimed effects and limited independent replication; low certainty.
Registry / identifierPMID 14523363